Body Handbook კატალოგი პროფილი რეიტინგი
ჯანდაცვა BODY HANDBOOK
ჯანდაცვა · §658
Resmetirom for Advanced Fatty Liver
There is now a pill that can shrink the scarring of advanced fatty liver disease, which no drug had ever done. Resmetirom, sold as Rezdiffra and FDA-approved in 2024, is the first to reverse both the inflammation and scarring of MASH on a one-year biopsy Harrison et al. 2024. It works for roughly one in three patients, costs about $47,000 a year at list, and only for scarring at the F2 to F3 stage. If your liver enzymes keep creeping up, know its name.
გადაწყვიტე · ყოველდღე მტკიცებულება ზომიერი თავი ჯანდაცვა

It is a liver-targeted thyroid switch, though not a thyroid pill. It tells only the liver to burn its own fat, so heart rate, blood pressure, and thyroid tests barely move 1. On biopsy, MASH cleared in about 30% of patients versus 10% on placebo, and scarring dropped a stage in about 26% versus 14% 2. One in three clears, one in four un-scars a step, and the other two-thirds don't.

Why the hurry on a silent disease. You feel nothing as fatty liver drifts to scarred to cirrhotic. At F3, roughly 5 to 10% of patients slip into cirrhosis a year, and MASH is now the top reason U.S. women need a transplant 3.

This is a decision to bring to a hepatologist, not a bottle to grab. The first move is proving your scarring is in the approved band.

Weight loss is still the stronger lever: losing 7 to 10% of body weight cleared MASH in about nine of ten people who kept it off 4, and GLP-1 drugs like tirzepatide do that plus likely reverse MASH on top 5. Resmetirom is the add-on when that isn't happening.

You will not feel this working. That is the point, and the hard part.

  • Early on. Nausea and loose stools settle; by month six, LDL is down around 15% without touching your statin 2.
  • Year one. A repeat FibroScan shows less fat and, in about a quarter of responders, less scarring. The number the drug exists to move, finally moving.
  • Beyond. The bet is that the scan which would have crept into cirrhosis stays flat, and the transplant never comes.

The price is the real obstacle. List is near $47,400 a year, but most insured patients pay closer to $10 a month through the copay program 6. Some payors demand a biopsy the label does not require. It is not approved in Europe, the UK, or Japan as of 2026.

The fine print — when to skip it, and what people get wrong
  • Not a cure. Two-thirds don't clear at a year, and even responders need monitoring.
  • Not a thyroid change. At these doses your TSH, T4, heart rate, and weight hold steady; levothyroxine rarely needs adjusting 2.
  • Not fully proven. Biopsy gain is a surrogate; the trial confirming fewer cirrhosis cases reads out around 2027 to 2028 7.
  • Skip in advanced cirrhosis with liver failure (Child-Pugh B or C), pregnancy, planning pregnancy, or breastfeeding 8.
  • Enzyme bumps are more common than on placebo; the drug is held above five times normal or if liver symptoms appear 8.
References
  1. 1Harrison et al. (2019). Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. link
  2. 2Harrison et al. (2024). A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine. link
  3. 3Younossi et al. (2023). The Global Epidemiology of Nonalcoholic Steatohepatitis (NASH) and Associated Risk Factors. Hepatology. link
  4. 4Vilar-Gomez et al. (2015). Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. link
  5. 5Loomba et al. (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. link
  6. 6ICER (2024). Resmetirom for Nonalcoholic Steatohepatitis: Effectiveness and Value. link
  7. 7FDA (2024). FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. link
  8. 8Madrigal Pharmaceuticals (2024). REZDIFFRA (resmetirom) Prescribing Information. link
დაკავშირებული სახელმძღვანელოში (4)
ეხმარება
  • — This is the first pill to reverse the inflammation and scarring of advanced fatty liver — it's the drug for the dangerous end of MASLD.
ალტერნატივები
  • — On top of weight loss, GLP-1s improve fatty liver — overlapping territory with the dedicated MASH drug resmetirom.
  • — Before this $47k drug, vitamin E is the cheap, older option with biopsy evidence in some MASH patients — worth discussing first.
დაკავშირებული
  • — Knowing how to read a liver panel makes sense of the lab numbers your doctor watches while you're on this drug.
·
658